IN2014DN09830A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09830A
IN2014DN09830A IN9830DEN2014A IN2014DN09830A IN 2014DN09830 A IN2014DN09830 A IN 2014DN09830A IN 9830DEN2014 A IN9830DEN2014 A IN 9830DEN2014A IN 2014DN09830 A IN2014DN09830 A IN 2014DN09830A
Authority
IN
India
Prior art keywords
formula
vivo
exhibits
correction
enabling
Prior art date
Application number
Inventor
Chenfeng Ke
Anthony P Davis
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bristol filed Critical Univ Bristol
Publication of IN2014DN09830A publication Critical patent/IN2014DN09830A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/10—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A water- soluble compound of the formula (I): (Formula (I)) wherein R9 and R10 are suitably hydrophilic substituents which may be used to selectively bind to a target saccharide such as glucose and which exhibits a detectable spectroscopic response to such binding, thus enabling its use in the detection and correction of blood glucose concentrations in vivo.
IN9830DEN2014 2012-04-27 2013-04-26 IN2014DN09830A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1207392.0A GB201207392D0 (en) 2012-04-27 2012-04-27 Novel compounds
PCT/GB2013/051079 WO2013160701A1 (en) 2012-04-27 2013-04-26 Anthracenyl - tetralactam macrocycles and their use in detecting a target saccharide

Publications (1)

Publication Number Publication Date
IN2014DN09830A true IN2014DN09830A (en) 2015-08-07

Family

ID=46330449

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9830DEN2014 IN2014DN09830A (en) 2012-04-27 2013-04-26

Country Status (9)

Country Link
US (2) US9610365B2 (en)
EP (1) EP2855439B1 (en)
CN (1) CN104428290B (en)
AU (1) AU2013254450A1 (en)
CA (1) CA2910581A1 (en)
GB (2) GB201207392D0 (en)
HK (1) HK1209112A1 (en)
IN (1) IN2014DN09830A (en)
WO (1) WO2013160701A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201207392D0 (en) 2012-04-27 2012-06-13 Univ Bristol Novel compounds
US10800747B2 (en) 2017-03-15 2020-10-13 Ziylo Ltd Macrocyclic compounds
CN113164764A (en) * 2018-09-19 2021-07-23 兹洛有限公司 Glucose-sensitive insulin and use thereof
US11410752B2 (en) 2019-07-30 2022-08-09 Emd Millipore Corporation Method of synthesizing chemical compounds
RU2752711C2 (en) * 2019-11-18 2021-07-30 Общество с ограниченной ответственностью «Лаборатория межклеточных технологий «Интерсел Рэнд» (ООО «Интерсел Рэнд») Method and device for spectroscopy of living tissue

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268159B2 (en) * 2000-06-02 2005-09-15 Eisai Inc. Delivery systems for bioactive agents
JP2003073399A (en) 2001-08-31 2003-03-12 Japan Science & Technology Corp Fluorescence-emitting modified protein
US7179616B1 (en) 2002-10-07 2007-02-20 University Of Notre Dame Du Lac Method for detecting phosphatidylserine on the surface of cells
US8642014B2 (en) * 2007-01-30 2014-02-04 Seta Biomedicals, Llc Luminescent compounds
WO2011059457A1 (en) * 2009-11-16 2011-05-19 University Of Notre Dame Du Lac High performance luminescent compounds
WO2011087521A1 (en) 2010-01-13 2011-07-21 University Of Notre Dame Du Lac Chemiluminescent dyes and dye-stained particles
GB201207392D0 (en) 2012-04-27 2012-06-13 Univ Bristol Novel compounds

Also Published As

Publication number Publication date
CN104428290A (en) 2015-03-18
US9937272B2 (en) 2018-04-10
WO2013160701A1 (en) 2013-10-31
GB201207392D0 (en) 2012-06-13
US20170266321A1 (en) 2017-09-21
GB2517345A (en) 2015-02-18
HK1209112A1 (en) 2016-03-24
CA2910581A1 (en) 2013-10-31
GB201420937D0 (en) 2015-01-07
AU2013254450A1 (en) 2014-11-27
US9610365B2 (en) 2017-04-04
EP2855439B1 (en) 2017-06-14
US20150147275A1 (en) 2015-05-28
CN104428290B (en) 2017-11-14
EP2855439A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
NZ597517A (en) 5-fluoropyrimidinone derivatives
WO2014089209A3 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
MA32383B1 (en) Indazole derivatives with phenyl and benzodoxynil alternatives
WO2014062720A3 (en) Methods of treating cancer
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
EA201591064A1 (en) NEW PYRIDINE DERIVATIVES
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PH12012501905A1 (en) Quinoline derivatives and their use as fungicides
EA201591527A1 (en) NEW PYRIDINE DERIVATIVES
WO2013089882A3 (en) Recurrent gene fusions in breast cancer
WO2012158780A3 (en) Lung cancer signature
WO2015077635A8 (en) Macromolecular antioxidants based on dual type moiety per molecule: structures methods of making and using the same
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
IN2015DN00636A (en)
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
IN2014DN09830A (en)
NI201100149A (en) DERIVATIVES OF TIADIAZOLES AND OXADIAZOLES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY.
MX342947B (en) Treatment of type 2 diabetes.
TR201909923T4 (en) Composition containing the pyrazole derivative for the prevention or treatment of kidney disease.
MX2014004920A (en) Novel pyrazine derivatives.
EA201270256A1 (en) DERIVATIVES OF T1-SUBSTITUTED 5-FLUOR-2-OXOPYRIMIDINON-1 (2H) -KARBOXAMID
EA201100730A1 (en) COMPLEX INCLUSION OF PINOCEMBRIN WITH CYCLODEXTRIN, METHOD FOR ITS PREPARATION AND APPLICATION
WO2013169631A3 (en) Wnt protein signalling inhibitors
TR201903918T4 (en) Compositions containing a dispersing agent and their preparation.